GLP-1 units vs. milligrams: what the dosing confusion actually means

What's this video probably claiming?

Based on the caption and hashtag cluster, this creator is almost certainly walking viewers through the difference between units (as marked on an insulin syringe) and milligrams (the actual drug concentration listed on a vial or pen). This is a genuinely common point of confusion, especially as compounded semaglutide and tirzepatide have flooded the market and patients are suddenly handling vials and syringes themselves for the first time. The creator frames this as the number-one dosing mistake they see, suggesting they work with or closely follow GLP-1 patients. The claim that this confusion can cause underdosing, overdosing, or stalled progress is directionally reasonable. The framing as a potential "medical emergency" is the part worth scrutinizing closely, because the severity of that claim depends heavily on context and concentration.

What does the science actually show?

The units-versus-milligrams confusion is real and documented in medication error literature well before GLP-1s went mainstream. A 2023 analysis in Diabetes Care (Grunberger et al.) flagged that the rapid expansion of compounded injectable GLP-1 products created a new class of dosing risk because patients were not trained on syringe-based administration the way insulin-dependent diabetics historically were. Compounded semaglutide vials vary in concentration, commonly 2 mg/mL, 5 mg/mL, or 10 mg/mL depending on the compounding pharmacy. If a patient draws "20 units" on a U-100 syringe from a 5 mg/mL vial, they are drawing 0.2 mL, which equals 1 mg of semaglutide. From a 10 mg/mL vial, the same 20 units delivers 2 mg. That is a twofold dosing error from one simple concentration swap, and it is not hypothetical. The FDA issued warnings in 2024 specifically about dosing errors with compounded semaglutide, citing concentration variability as a contributing factor.

Where does the social media noise diverge from clinical reality?

The gap here is mostly about severity framing and what actually constitutes an emergency. Semaglutide has a very wide therapeutic index compared to something like insulin. Serious acute toxicity from a doubled dose is unlikely in most adults, though nausea, vomiting, and accelerated side effects are real. The word "medical emergency" in the caption overstates what a typical dosing error would produce for most patients. That said, tirzepatide at higher concentrations (Mounjaro is 2.5 mg per 0.5 mL; some compounded versions differ significantly) does carry more acute GI risk with overdose. The bigger clinical problem the research actually identifies is chronic underdosing, not acute overdose. Wilding et al. (2021, NEJM) showed efficacy for semaglutide is dose-dependent, and patients who never titrate properly simply do not get the weight loss outcomes the trials demonstrated. Stalled progress from underdosing is a real, under-discussed issue that this creator is right to flag.

What should you actually know?

If you are using a compounded GLP-1 medication drawn from a vial, you need to know three things before you inject anything: the concentration of your specific vial in mg/mL, the volume you are drawing in milliliters, and how those two numbers multiply to your actual milligram dose. Your prescribing clinician or pharmacist should provide a written dosing chart that does this math for you based on your specific vial concentration. If they did not, that is a gap in your care. The FDA has a published guidance on avoiding these errors. Relying on TikTok math for injectable medication dosing is not a substitute for that conversation. Compounded GLP-1 products are also not equivalent to FDA-approved branded formulations in terms of verified concentration accuracy, a distinction that matters when you are trying to dose precisely. Always confirm your vial concentration each time you refill, because compounding pharmacies do change their formulations.